Immune Therapeutics Receives Approval for Lodonal™ from the Dominican Republic’s Ministry of Health and Social Assistance
ORLANDO, Fla., Feb. 02, 2017 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN), a global specialty pharmaceutical company dedicated to advancing the science of affordable, non-toxic therapies in Emerging Markets, announced today that the Dominican Republic’s Ministry of Health and Social Assistance has issued a Certificate of Pharmaceutical Product (COPP) for Lodonal™ (Naltrexone). This certificate grants approval for the manufacturing and export of LodonalTM for the treatment of HIV/AIDS, opportunistic infections, inflammatory disease and cancer in the dosages specified in the filings.
Company to Host Investor Conference Call to Discuss Positive Developments
ORLANDO, Fla., Jan. 30, 2017 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (IMUN), a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today issued a Special Letter to Shareholders from its Chief Executive Officer, Noreen Griffin, which summarizes some of the Company’s achievements in 2016 and, more importantly, discusses its growth outlook for 2017 and beyond. The Company will be hosting an investor conference call, which will include a question and answer session, to discuss today’s Special Letter to Shareholders. Dial-in information for the call is provided below.
ORLANDO, Fla., Jan. 27, 2017 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced that it will hold a special investor conference call to discuss the Company’s recent operating highlights and its financial and operational outlook for 2017. The conference call will follow a press release that will be issued pre-market on January 30, 2017 summarizing these topics.